US 12,275,797 B2
Anti-CD37 antibodies and anti-CD20 antibodies, compositions and methods of use thereof
Simone Oostindie, Utrecht (NL); Frank Beurskens, Utrecht (NL); Ronald Taylor, Keswick, VA (US); Margaret Lindorfer, Keswick, VA (US); Hilma Van Der Horst, Utrecht (NL); Martine E. D. Chamuleau, Amsterdam (NL); Tuna Mutis, Amsterdam (NL); Paul Parren, Odijk (NL); and Esther Breij, Utrecht (NL)
Assigned to GENMAB HOLDING B.V., Utrecht (NL)
Appl. No. 17/253,276
Filed by GENMAB HOLDING B.V., Utrecht (NL)
PCT Filed Jun. 24, 2019, PCT No. PCT/EP2019/066700
§ 371(c)(1), (2) Date Dec. 17, 2020,
PCT Pub. No. WO2019/243636, PCT Pub. Date Dec. 26, 2019.
Claims priority of provisional application 62/688,921, filed on Jun. 22, 2018.
Prior Publication US 2021/0371539 A1, Dec. 2, 2021
Int. Cl. A61K 39/395 (2006.01); A61K 45/06 (2006.01); C07K 16/28 (2006.01)
CPC C07K 16/2896 (2013.01) [A61K 45/06 (2013.01); C07K 16/2887 (2013.01); C07K 2317/24 (2013.01); C07K 2317/565 (2013.01); C07K 2317/72 (2013.01)] 18 Claims
 
1. A composition comprising (a) a first antibody and a second antibody, wherein the first antibody comprises a first antigen-binding region capable of binding to human CD37 and a first Fc region of a human IgG, and the second antibody comprises a second antigen-binding region capable of binding to human CD20 and a second Fc region of a human IgG, wherein both the first Fc region and the second Fc region comprise a substitution of an amino acid at a position corresponding to E430, E345 or S440 in human IgG1 when using the EU numbering system, with the proviso that the substitution in S440, if present, is S440Y or S440W, and (b) a carrier,
wherein the first antigen-binding region comprises a variable heavy chain (VH) region comprising CDR sequences HCDR1, HCDR2 and HCDR3 and a variable light chain (VL) region comprising CDR sequences LCDR1, LCDR2 and LCDR3 selected from the group consisting of:
a. SEQ ID NOs: 22, 23, and 24, respectively, and SEQ ID NO: 26, the sequence EAS, and SEQ ID NO: 27, respectively,
b. SEQ ID NOs: 29, 30, and 31, respectively, and SEQ ID NO: 33, the sequence AAS, and SEQ ID NO: 34, respectively,
c. SEQ ID NOs: 36, 37, and 38, respectively, and SEQ ID NO: 40, the sequence KAS, and SEQ ID NO: 41, respectively,
d. SEQ ID NOs: 43, 44, and 45, respectively, and SEQ ID NO: 47, the sequence YAS, and SEQ ID NO: 48, respectively,
e. SEQ ID NOs: 43, 44, and 45, respectively, and SEQ ID NO: 47, the sequence YAS, and SEQ ID NO: 58, respectively,
f. SEQ ID NOs: 8, 9, and 10, respectively, and SEQ ID NO: 12, the sequence VAT, and SEQ ID NO: 13, respectively, and
g. SEQ ID NOs: 15, 16, and 17, respectively, and SEQ ID NO: 19, the sequence FAK, and SEQ ID NO: 20, respectively.